Western Regional Blog – BC, YK, AB, NWT and Nunavut
Astra Zeneca Canada Inc., is applying for the second time to pCODR to have Olaparib/Lynparza recommended as a treatment for those who have tested positive for a BRCA gene mutation and who have platinum-sensitive recurrent epithelial, ovarian, fallopian tube or primary peritoneal cancer. The new research results from their Phase III clinical trial have warranted this second application.
Ovarian Cancer Canada is in the process of preparing a Patient Impact Report and are surveying survivors and caregivers for their feedback. The experiences of people who have been diagnosed with ovarian cancer and their caregivers are important considerations in the drug funding approval process and we want to make sure that survivors and caregivers alike can make their voices heard.
There is certain criteria that must be met before someone can complete the survey which can be seen through the links below, but it is not restricted only to people who actually received Olaparib/Lynparza.
For those diagnosed: https://www.surveymonkey.com/r/olapensur
For caregivers: https://www.surveymonkey.com/r/olapcare